{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-PD-L1+Monoclonal+Antibody+MPDL3280A", "query": { "intervention": "Anti-PD-L1 Monoclonal Antibody MPDL3280A" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 180, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-PD-L1+Monoclonal+Antibody+MPDL3280A&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-08T11:54:32.440Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02733042", "title": "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma", "Leukemia, Lymphocytic, Chronic, B-Cell" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2016-05-11", "completion_date": "2022-08-21", "has_results": true, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-08T11:54:32.440Z", "location_count": 19, "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02733042" }, { "nct_id": "NCT02367781", "title": "A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Squamous Non-Small Cell Lung" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 723, "start_date": "2015-04-16", "completion_date": "2021-01-18", "has_results": true, "last_update_posted_date": "2021-08-09", "last_synced_at": "2026-10-08T11:54:32.440Z", "location_count": 57, "location_summary": "Springdale, Arkansas • Oakland, California • Roseville, California + 52 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02367781" }, { "nct_id": "NCT05394337", "title": "Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Malignancy" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2023-02-23", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-08T11:54:32.440Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05394337" }, { "nct_id": "NCT04310020", "title": "Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage II Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2021-01-13", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-08T11:54:32.440Z", "location_count": 170, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Jonesboro, Arkansas + 107 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04310020" }, { "nct_id": "NCT03237780", "title": "Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Recurrent Bladder Urothelial Carcinoma", "Recurrent Renal Pelvis Urothelial Carcinoma", "Recurrent Ureter Urothelial Carcinoma", "Recurrent Urethral Urothelial Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Unresectable Bladder Urothelial Carcinoma", "Unresectable Renal Pelvis Urothelial Carcinoma", "Unresectable Ureter Urothelial Carcinoma", "Unresectable Urethral Urothelial Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography with Contrast", "type": "PROCEDURE" }, { "name": "Eribulin Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2018-07-20", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-08T11:54:32.440Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Buena Park, California • Duarte, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Buena Park", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03237780" }, { "nct_id": "NCT02486718", "title": "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1280, "start_date": "2015-10-31", "completion_date": "2026-08-26", "has_results": true, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-08T11:54:32.440Z", "location_count": 45, "location_summary": "Fayetteville, Arkansas • Encinitas, California • Fountain Valley, California + 38 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02486718" }, { "nct_id": "NCT02425891", "title": "A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 902, "start_date": "2015-06-23", "completion_date": "2021-08-31", "has_results": true, "last_update_posted_date": "2022-07-19", "last_synced_at": "2026-10-08T11:54:32.440Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Springdale, Arkansas • Oakland, California + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02425891" }, { "nct_id": "NCT01810913", "title": "Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma", "Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7", "Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 613, "start_date": "2013-03-22", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-08T11:54:32.440Z", "location_count": 338, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01810913" }, { "nct_id": "NCT04081688", "title": "Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab 1200 MG in 20 ML Injection", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Varlilumab 3 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2019-09-11", "completion_date": "2024-04-30", "has_results": true, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-08T11:54:32.440Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04081688" }, { "nct_id": "NCT02935361", "title": "Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Guadecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2016-11-02", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-08T11:54:32.440Z", "location_count": 5, "location_summary": "Los Angeles, California • Baltimore, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02935361" } ] }